肿瘤坏死因子α抑制剂（TNFαI）引起的银屑病皮疹是成人中众所周知的现象。然而，有关儿童这种反应的数据有限。为了描述炎症性肠病 (IBD) 儿科患者、TNFαI 诱导的银屑病样皮疹的临床特征以及各种治疗方案的结果。我们回顾了儿科患者的医疗图表 ( 2006-2022年期间出现TNFαI诱发的银屑病样皮疹的IBD患者（年龄<18岁）。在接受TNFαI治疗的454名IBD患者中，58例（12.8%）被诊断为TNFαI诱发的银屑病样皮疹，其中51例被纳入研究学习。男女比例为1:1.3。出现皮疹的中位年龄为 14.1 [四分位距，12.11-16.05] 岁。开始治疗后出现出疹的中位时间为 15 [四分位距，7-24] 个月。所有患者均接受局部类固醇治疗，其中 17 例（33%）需要全身治疗（光疗、甲氨蝶呤或阿维A）。 16 名患者（31%）因顽固性皮疹需要停止 TNFαI 治疗。女性患者、炎性脱发患者以及接受甲氨蝶呤或光疗治疗的患者更容易停止TNFαI。TNFαI诱发的银屑病皮疹在IBD儿童患者中很常见。皮疹可能会在治疗开始后数月甚至数年出现。所描述的患者中近三分之一由于顽固性皮疹而不得不更换治疗。这表明有效的管理需要采用多学科方法。© 作者 2024。由牛津大学出版社代表英国皮肤科医师协会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

Tumor necrosis factor α inhibitors (TNFαI)-induced psoriasiform eruptions are a well-known phenomenon among adults. However, data are limited regarding this reaction in children.To describe in pediatric patients with inflammatory bowel diseases (IBD), the clinical characteristics of TNFαI-induced psoriasiform eruptions and the outcomes of various therapeutic options.We reviewed the medical charts of pediatric patients (aged <18 years old) with IBD who developed TNFαI-induced psoriasiform eruptions during 2006-2022.Among 454 patients with IBD treated with TNFαI, 58 (12.8%) were diagnosed with TNFαI-induced psoriasiform eruptions, of whom 51 were included in the study. The female to male ratio was 1:1.3. The median age at skin eruption was 14.1 [interquartile range, 12.11-16.05] years. The median elapsed time to eruption appearance was 15 [interquartile range, 7-24] months after initiation of the treatment. All the patients were treated with topical steroids and 17 (33%) needed systemic treatment (phototherapy, methotrexate or acitretin). Sixteen patients (31%) needed to stop TNFαI treatment due to an intractable eruption. Female patients, patients with inflammatory alopecia and patients who were treated with methotrexate or phototherapy were more prone to stop TNFαI.TNFαI-induced psoriasiform eruptions are common in pediatric patients with IBD. The eruption may appear months or even years after treatment initiation. Almost one-third of the described patients had to replace their treatment due to a recalcitrant cutaneous eruption. This indicates that a multidisciplinary approach is required for effective management.© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.